Monday 9 November 2026 Export NXL’s income statement to Excel — free account

Nexalin Technology, Inc.

NXL

Nexalin Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $301,600.00, up 78.8% from fiscal 2024.

Revenue: −82.7%
EPS: −10.0%
Free cash flow: −97.2%

Quarter to June 2026, against a year earlier

1.47 0.07 +5.00%

Follow NXL

Alert me

Market cap: $1.7M
P/E: n/m
Fwd P/E: n/m
Dividend yield: —
F-score: 5/9
ROIC: −1,108.8%
Net debt / EBITDA: 0.4×
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Net bought: —
Trades: 0 sells · 0 buys
Ownership: 0.00%

Capital & Financial Ratios $m

Size

Market Cap 2

Revenue ttm 0

Net income ttm (9)

Free cash flow ttm (6)

Net debt Q (1)

Valuation

P/E n/m

Forward P/E n/m

Price / sales 4.8

Forward P/S Powerpack

Price / FCF n/m

Price / book 0.7

Financial health

Current ratio Q 1.3

Debt / equity Q n/m

Interest coverage Q (22,473.0)

Growth

Revenue growth Q −82.7%

Operating income growth Q −38.6%

EPS, this year +23.9%

EPS, next year A +33.9%

Revenue, next year A −36.3%

EPS, past 5 yrs —

EPS, next 5 yrs A —

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates; n/m is not meaningful, as a P/E on a loss. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 8.16%

10-year low 10-year high

P/B against its own 10 years 1.75%

10-year low 10-year high

EV/Sales against its own 10 years 0.50%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	3	4	1
Receivables	0	0	0	0
Inventory	0	0	0	0
Other	—	—	—	—
	3	4	4	2

	2023	2024	2025	Q'26
Payables	0	0	0	0
ST’ Debt	—	—	—	—
Other	—	—	—	0
	0	1	1	1

Compound Annual Growth %

	10y	5y	3y
Sales	—	4.42%	(38.89%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(11.89%)

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(3.30)	(3.30)	—	—	—
’25	(4.50)	(3.00)	(3.90)	(3.90)	(15.01)
’24	(4.20)	(5.11)	(6.91)	(8.41)	(24.92)
’23	(3.00)	(3.30)	(9.31)	(3.00)	(18.92)
’22	(2.42)	(2.84)	(0.90)	(3.30)	(9.01)
’21	—	—	(12.22)	—	(42.89)
’20	—	—	—	—	(28.53)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	0	—	—	—
’25	0	0	0	0	0
’24	0	0	0	0	0
’23	0	0	0	0	0
’22	0	0	1	0	1
’21	—	—	0	—	0
’20	—	—	—	—	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(1)	(1)	(1)	(1)	(5)
’24	(1)	(1)	(1)	(1)	(4)
’23	(1)	(1)	(1)	(1)	(4)
’22	0	0	(1)	(1)	(2)
’21	—	—	(1)	0	(1)
’20	—	—	—	(1)	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(2)	—	—	—
’25	(1)	(1)	(1)	(1)	(5)
’24	(1)	(1)	(1)	(1)	(4)
’23	(1)	(1)	(1)	(1)	(4)
’22	0	0	(1)	(8)	(9)
’21	—	—	(1)	0	(1)
’20	—	—	—	(1)	(1)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	0	0	0	1	0	0	0	0		+6.4%	0	0	—	+5.9%
	Gross margin, %	—	—	—	(5.21)	88.06	85.08	72.51	76.87	78.30	79.68	86.14		+84.9 pt	Powerpack Nexalin Technology, Inc.’s next three years, line by line Analysts expect revenue to grow 5.9% a year to 2028 — slower than the 6.4% of the last 6 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	—	—	—	(5)	(3)	(6)	(2)	(5)	(8)	(8)	(9)		+8.6%
	EBT margin, %	—	—	—	(2,421.02)	(1,401.19)	(4,217.90)	(128.48)	(4,199.37)	(4,512.15)	(2,725.83)	(4,138.49)		(304.8) pt
	Net income	—	—	—	(5)	(3)	(6)	(2)	(5)	(8)	(8)	(9)		+8.6%
Per share, $
Per share, $	Revenue	—	—	—	0.03	2.04	1.02	7.12	0.45	0.55	0.55	0.31		+63.9%
	Earnings	—	—	—	(0.69)	(28.53)	(42.89)	(9.01)	(18.92)	(24.92)	(15.01)	(14.41)		+67.1%
	Cash flow	—	—	—	(0.09)	(7.24)	(7.60)	(11.94)	(15.65)	(12.85)	(9.08)	(8.70)		+114.5%
	Capex	—	—	—	0.00	0.00	0.00	(36.61)	(0.49)	(0.55)	(0.18)	(0.30)		n/m
	Free cash flow	—	—	—	(0.09)	(7.24)	(7.60)	(48.55)	(16.14)	(13.41)	(9.26)	(9.00)		+115.2%
	Book value	—	—	—	(0.16)	(13.33)	(11.87)	29.52	13.09	11.98	6.87	2.16		n/m
	Shares, m	—	—	—	7	0	0	0	0	0	1	1		(35.1%)
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0
	P/S	—	—	—	0.00	0.00	0.00	3.31	26.45	150.65	30.30	4.77		30.1
	P/B	—	—	—	0.00	0.00	0.00	0.80	0.91	6.91	2.44	0.68		1.6
	EV/Sales	—	—	—	0.00	0.00	0.00	(1.98)	(0.14)	130.05	17.97	0.16		20.8
	EV/FCF	—	—	—	(7.58)	(7.58)	(7.58)	1.18	0.00	(1.99)	(0.45)	(0.01)		(3.4)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(1)	(1)	(1)	(2)	(4)	(4)	(5)	(6)		+39.3%
	Capex	—	—	—	—	0	—	(7)	0	0	0	0		+176.5%
	Free cash flow	—	—	—	(1)	(1)	(1)	(9)	(4)	(4)	(5)	(6)		+39.8%
Balance, $m
Balance, $m	Working capital	—	—	—	(1)	(1)	(2)	5	3	3	3	0		n/m
	Net debt	—	—	—	1	0	(1)	(7)	(3)	(3)	(4)	(1)		n/m
	Shareholders’ equity	—	—	—	(1)	(2)	(2)	5	3	4	4	2		n/m
Returns, %
Returns, %	ROA	—	—	—	0.00	(2,946.75)	(1,393.72)	(41.48)	(84.03)	(193.70)	(185.64)	(187.89)		(185.6) pt
	ROIC	—	—	—	0.00	0.00	0.00	0.00	(1,378.85)	(2,471.51)	(21,146.42)	(1,108.82)		(21,146.4) pt
	ROE	—	—	—	0.00	245.77	371.49	(89.43)	(107.05)	(221.06)	(221.50)	(240.25)		(221.5) pt
People
People	Employees	—	—	—	—	—	—	6	6	6	8	—		+10.1%
	Revenue/emp, $m	—	—	—	0.00	0.00	0.00	0.22	0.02	0.03	0.04	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 2 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BJDX Bluejay Diagnostics, Inc.	$2.6M	— (loss-making)	— (loss-making)	—	n/m	+20.05% (above 0%: growing)	0.00%	0.00%	Compare
IVF INVO Fertility, Inc	$2.6M	— (loss-making)	— (loss-making)	+16.73% (above 0%: growing)	n/m	+35.07% (above 0%: growing)	35.06%	(59.28%)	Compare
CODX Co-Diagnostics, Inc.	$2.4M	— (loss-making)	— (loss-making)	+1.96% (above 0%: growing)	n/m	+17.47% (above 0%: growing)	72.73%	(3,733.17%)	Compare
ICCM IceCure Medical Ltd.	$2.3M	— (loss-making)	— (loss-making)	−0.69% (below 0%: shrinking)	n/m	+3.88% (above 0%: growing)	32.38%	(466.19%)	Compare
NUVOQ Holdco Nuvo Group D.G Ltd.	$2.1M	— (loss-making)	—	—	n/m	−1.05% (below 0%: shrinking)	0.00%	0.00%	Compare
ADGM Adagio Medical Holdings, Inc.	$1.8M	— (loss-making)	—	−33.50% (below 0%: shrinking)	n/m	−12.86% (below 0%: shrinking)	0.00%	0.00%	Compare
NXL Nexalin Technology, Inc.	$1.7M	— (loss-making)	— (loss-making)	−82.72% (below 0%: shrinking)	n/m	−97.23% (below 0%: shrinking)	72.95%	(18,420.49%)
GCTK GlucoTrack, Inc.	$1.7M	— (loss-making)	— (loss-making)	+342.48% (above 0%: growing)	n/m	+3.42% (above 0%: growing)	0.00%	0.00%	Compare
DHAI DIH Holding US, Inc.	$1.6M	— (loss-making)	—	−30.67% (below 0%: shrinking)	n/m	−167.90% (below 0%: shrinking)	50.33%	(33.62%)	Compare
Median of peers	$2.2M	—	—	+0.64%	—	+3.65%	16.19%	(16.81%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 6 November 2026

Ownership

Directors and executive officers, together 17.09%

Greenlight Ventures, LLC 10.79%

Mark White 7.31%

David Owens, M.D. 7.24%

Alumni Capital LP 6.81%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Nexalin Technology, Inc. (NXL) Latest News

27 Oct

Impact 4 · 9:00 AM · GlobeNewswire

Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease

8 Oct

Impact 4 · 8:30 AM · GlobeNewswire

Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing

1 Oct

Impact 4 · 10:03 AM · InvestorsHub

Nexalin Technology Signs South America Distribution Agreement for Nexalin Sync Commercialization

Impact 4 · 8:30 AM · GlobeNewswire

Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation

Impact 3 · 2:33 PM

Top Midday Gainers

29 Sep

Impact 4 · 9:00 AM · GlobeNewswire

Nexalin Technology Taps Neuromodulation Commercial Executive Robert DiTota to Advise on its Global Commercialization Strategy

3 Sep

Impact 4 · 8:30 AM

Nexalin Technology Announces New Secondary Analysis of Previously Published Clinical Trial Data Reveals Previously Unreported Improvements in Memory, Comprehension and Language Function in Alzheimer’s Patients; ADAS-Cog Subscale Analysis to Guide Design of Planned U.S. Alzheimer’s Pilot Study

16 Jun

Impact 3 · 9:15 AM

Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of Life

10 Jun

Impact 4 · 9:15 AM · GlobeNewswire

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.

Impact 4 · 9:01 AM · Benzinga

EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life

4 Jun

Impact 4 · 10:00 AM · GlobeNewswire

Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia

21 May

Impact 4 · 8:30 AM · GlobeNewswire

Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain Injury

19 May

Impact 4 · 8:30 AM · GlobeNewswire

Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial

28 Apr

Impact 4 · 9:15 AM · GlobeNewswire

Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia

22 Apr

Impact 4 · 9:35 AM · GlobeNewswire

Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment

15 Apr

Impact 4 · 10:00 AM

Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China

9 Apr

Impact 4 · 7:47 AM · GlobeNewswire

Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents

24 Feb

Impact 4 · 8:07 AM · GlobeNewswire

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

23 Feb

Impact 3 · 8:18 AM · GlobeNewswire

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

13 Feb

Impact 3 · 9:00 AM · ACCESS Newswire

Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

5 Feb

Impact 4 · 8:37 AM · GlobeNewswire

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care

2 Feb

Impact 4 · 8:45 AM · GlobeNewswireMT NewswiresZacksBioPharma DiveGuruFocus.comSimply Wall St.Medical Device NetworkSimply Wall St.

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

14 Jan

Impact 4 · 9:00 AM · GlobeNewswire

Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

3 Dec

Impact 4 · 8:00 AM · GlobeNewswire

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program

2 Dec

Impact 3 · 8:00 AM · GlobeNewswireMT NewswiresMotley FoolGuruFocus.comGuruFocus.comMotley Fool

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4

18 Nov

Impact 4 · 9:00 AM · GlobeNewswire

Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

13 Nov

Impact 4 · 9:15 AM · GlobeNewswire

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

5 Nov

Impact 4 · 8:30 AM · GlobeNewswire

Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia

30 Oct

Impact 4 · 8:30 AM · GlobeNewswireMT NewswiresMedical Device NetworkMT NewswiresGuruFocus.comMT NewswiresMedical Device NetworkClinical Trials Arena

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

21 Oct

Impact 4 · 9:00 AM · GlobeNewswireMT NewswiresBenzingaTipRanksMT NewswiresSimply Wall St.ZacksMT Newswires

Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Nexalin Technology, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 6 November 2026

Ownership

Nexalin Technology, Inc. (NXL) Latest News

27 Oct

8 Oct

1 Oct

29 Sep

3 Sep

16 Jun

10 Jun

4 Jun

21 May

19 May

28 Apr

22 Apr

15 Apr

9 Apr

24 Feb

23 Feb

13 Feb

5 Feb

2 Feb

14 Jan

3 Dec

2 Dec

18 Nov

13 Nov

5 Nov

30 Oct

21 Oct

Stockrow Weekly